Market Place
Sourcing Support
All News #Library
Biotech
Aptose Spotlights Tuspetinib`s AML Responses at ASH 2025
06 Dec 2025 //
GLOBENEWSWIRE
Aptose Reports Third Quarter 2025 Results
13 Nov 2025 //
GLOBENEWSWIRE
Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH
03 Nov 2025 //
GLOBENEWSWIRE
Aptose’s Tuspetinib Excels with Standard Care in AML Patients
16 Oct 2025 //
GLOBENEWSWIRE
Aptose, Hanmi Pharma Extend Loan For Tuspetinib In Aml Triplet
22 Sep 2025 //
GLOBENEWSWIRE
Aptose Opens 160 mg Cohort in Ph 1/2 Tuscany Triple Drug Trial
06 Aug 2025 //
GLOBENEWSWIRE
Aptose Upgraded to Trade on OTCQB Market
01 Jul 2025 //
GLOBENEWSWIRE
Aptose and Hanmi`s New Loan Agreement for Tuspetinib in AML
20 Jun 2025 //
GLOBENEWSWIRE
CEO props up Aptose`s Finances to Prevent Biotech from Going Bust
17 Jun 2025 //
FIERCE BIOTECH
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
01 Apr 2025 //
GLOBENEWSWIRE
Aptose Announces Reverse Share Split
18 Feb 2025 //
GLOBENEWSWIRE
Aptose Secures $25M Equity Facility & Launches ATM Program
13 Feb 2025 //
GLOBENEWSWIRE
Aptoses’ Tuspetinib Shows Responses In AML Ph 1/2 TUSCANY Trial
12 Feb 2025 //
GLOBENEWSWIRE
Aptose Announces Results from Special Meeting of Shareholders
05 Sep 2024 //
GLOBENEWSWIRE
Aptose Announces Adjournment of its Special Meeting of Shareholders
15 Aug 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.